Table 3.
Pathway Marker Transitions |
LM, pg/500 mg liver |
||||
---|---|---|---|---|---|
Quartile 1 | Quartile 3 | HCD | SOLE | FOLE | |
DHA bioactive metabolome | |||||
RvD1 | 375 | 215 | * | * | * |
RvD2 | 375 | 141 | * | * | * |
RvD3 | 375 | 147 | * | * | * |
RvD5 | 359 | 199 | * | * | * |
RvD6 | 359 | 159 | * | * | * |
PD1 | 359 | 153 | * | * | * |
10S,17S-diHDHA | 359 | 153 | 222 ± 93 | 173 ± 20 | 493 ± 217 |
10-epi-Δ15-trans-PD1 | 359 | 153 | 38.4 ± 17.5 | 20.5 ± 0.03 | 72.7 ± 46.8 |
Δ15-trans-PD1 | 359 | 153 | 25.2 ± 11.0 | 24.4 ± 2.7 | 68.6 ± 27.3 |
22-OH-PD1 | 375 | 153 | * | * | * |
22-COOH-PD1 | 389 | 153 | * | * | * |
MaR1 | 359 | 250 | * | * | * |
7S,14S-diHDHA | 359 | 250 | 50.3 ± 29.7 | 49.9 ± 7.1 | 233 ± 120 |
7-epi-Δ12-trans-MaR1 | 359 | 250 | 74.3 ± 35.5 | 77.8 ± 6.9 | 136 ± 40 |
Δ12-trans-MaR1 | 359 | 250 | 28.7 ± 15.1 | 46.6 ± 0.3 | 99.5 ± 24.8 |
4S,14S-diHDHA | 359 | 101 | 80.8 ± 39.1 | 41.6 ± 16.2 | 250 ± 101 |
DHA pathway markers | |||||
17-HDHA | 343 | 245 | 383 ± 64 | 243 ± 58 | 1,006 ± 141†§§ |
14-HDHA | 343 | 205 | 2,891 ± 311 | 2,375 ± 527 | 6,363 ± 1,300§ |
7-HDHA | 343 | 141 | 47.9 ± 15.2 | 35.0 ± 3.0 | 145 ± 32†§ |
4-HDHA | 343 | 101 | 124 ± 32 | 68.0 ± 12.0 | 309 ± 89 |
EPA bioactive metabolome | |||||
RvE1 | 349 | 195 | * | * | * |
RvE2 | 333 | 253 | * | * | * |
RvE3 | 333 | 201 | * | * | * |
LXA5 | 349 | 215 | * | * | * |
LXB5 | 349 | 221 | * | * | * |
5S,15S-diHEPE | 333 | 253 | 61.0 ± 50.7 | 30.4 ± 15.2 | 471 ± 399 |
EPA pathway markers | |||||
18-HEPE | 317 | 259 | 35.4 ± 21.6 | 323 ± 113 | 4,678 ± 388†††§§§ |
15-HEPE | 317 | 219 | 93.8 ± 54.9 | 480 ± 157 | 2,543 ± 152†††§§§ |
12-HEPE | 317 | 179 | 311 ± 151 | 3,042 ± 691 | 2,2809 ± 5,514††§ |
5-HEPE | 317 | 115 | 14.8 ± 0.8 | 59.9 ± 15.5 | 337 ± 43†††§§§ |
AA bioactive metabolome | |||||
LXA4 | 335 | 115 | * | * | * |
LXB4 | 351 | 221 | * | * | * |
5S,15S-diHETE | 335 | 235 | 96.8 ± 37.3 | 203 ± 28 | 162 ± 65 |
LTB4 | 335 | 195 | * | * | * |
5S,12S-diHETE | 335 | 195 | 16.3 ± 5.1 | 19.1 ± 4.5 | 69.9 ± 34.6 |
12epi-Δ6-trans-LTB4 | 335 | 195 | 11.1 ± 5.0 | 8.0 ± 1.0 | 2.6 ± 1.3 |
Δ6-trans-LTB4 | 335 | 195 | 13.3 ± 5.2 | 10.9 ± 0.4 | 3.3 ± 1.6 |
20-OH-LTB4 | 351 | 195 | * | * | * |
20-COOH-LTB4 | 365 | 195 | * | * | * |
PGD2 | 351 | 189 | 770 ± 489 | 792 ± 168 | 198 ± 72 |
PGE2 | 351 | 189 | 525 ± 393 | 197 ± 16 | 123 ± 56 |
PGF2α | 353 | 193 | 925 ± 413 | 1,731 ± 668 | 283 ± 105 |
TXB2 | 369 | 169 | 60.8 ± 45.8 | 24.6 ± 5.6 | 17.2 ± 6.3 |
AA pathway markers | |||||
15-HETE | 319 | 219 | 681 ± 135 | 1,383 ± 374 | 792 ± 85 |
12-HETE | 319 | 179 | 3,325 ± 374 | 5,051 ± 769 | 3,302 ± 246 |
5-HETE | 319 | 115 | 138 ± 29 | 113 ± 10 | 52.4 ± 3.7† |
Sum of proresolving mediators | 677 ± 250 | 667 ± 19 | 1,984 ± 1,040 | ||
Sum of proinflammatory mediators | 2,261 ± 1,130 | 2,758 ± 831 | 680 ± 253 | ||
Proresolution index | 0.3 | 0.2 | 2.9 | ||
(sum of proresolving mediators/sum of inflammatory mediators) |
LM values are means ± SE (n = 3). Quartile 1, M-H (parent ion); quartile 3, diagnostic ions in the MS-MS (daughter ion).
Below limits of detection (detection limit was ∼2 pg in tissue matrix). Ion suppression effect was 85–92%.
P < 0.05,
P < 0.01,
P < 0.001 vs. HCD.
P < 0.05,
P < 0.01,
P < 0.001 vs. SOLE.